Sonic Healthcare Limited: Strong Half-Year Financial Performance for FY 2026
Sonic Healthcare Limited (ASX: SHL) reported a solid financial performance for the half-year ended 31 December 2025, driven by strong revenue growth and disciplined cost control. Revenue increased by 17%, reaching AU$5.45 billion, while net profit rose 11% to AU$262 million. The company achieved organic growth of 5%, and its EBITDA improved by 10%, with a continued focus on cost control and operational efficiency.
Sonic's global operations performed robustly, with notable contributions from Germany, Switzerland, and the UK. Despite challenges in the USA, including the loss of a major payor contract and restructuring efforts, the company remains focused on expanding advanced diagnostics. Sonic also continued its capital management initiatives, including the sale and leaseback of properties and an increase in the interim dividend by 2.3%. The company is strategically poised for future growth, driven by targeted acquisitions and the realization of operational synergies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au
x
Daily Dose of Buy, Sell & Hold recommendations before the market opens.
Start Your 7 Days Free Trial Now!
We use cookies to help us improve, promote, and protect our services.
By continuing to use this site, we assume you consent to this.
Read our
Privacy Policy
and
Terms & Conditions
Sonic Healthcare Limited: Strong Half-Year Financial Performance for FY 2026
Sonic Healthcare Limited (ASX: SHL) reported a solid financial performance for the half-year ended 31 December 2025, driven by strong revenue growth and disciplined cost control. Revenue increased by 17%, reaching AU$5.45 billion, while net profit rose 11% to AU$262 million. The company achieved organic growth of 5%, and its EBITDA improved by 10%, with a continued focus on cost control and operational efficiency.
Sonic's global operations performed robustly, with notable contributions from Germany, Switzerland, and the UK. Despite challenges in the USA, including the loss of a major payor contract and restructuring efforts, the company remains focused on expanding advanced diagnostics. Sonic also continued its capital management initiatives, including the sale and leaseback of properties and an increase in the interim dividend by 2.3%. The company is strategically poised for future growth, driven by targeted acquisitions and the realization of operational synergies.
Customer Notice:
Nextgen Global Services Pty Ltd trading as Kapitales Research (ABN 89 652 632 561) is a Corporate Authorised Representative (CAR No. 1293674) of Enva Australia Pty Ltd (AFSL 424494). The information contained in this website is general information only. Any advice is general advice only. No consideration has been given or will be given to the individual investment objectives, financial situation or needs of any particular person. The decision to invest or trade and the method selected is a personal decision and involves an inherent level of risk, and you must undertake your own investigations and obtain your own advice regarding the suitability of this product for your circumstances. Please be aware that all trading activity is subject to both profit & loss and may not be suitable for you. The past performance of this product is not and should not be taken as an indication of future performance.
Kapitales Research, Level 13, Suite 1A, 465 Victoria Ave, Chatswood, NSW 2067, Australia | 1800 005 780 | info@kapitales.com.au